Future Science Group
Browse
- No file added yet -

An efficient and novel technology for the extraction of parasite genomic DNA from whole blood or cultureAn efficient and novel technology for the extraction of parasite genomic DNA from whole blood or culture

Download (10 kB)
dataset
posted on 2019-11-29, 08:50 authored by David J Clark, CATHERINE MOORECATHERINE MOORE, Marc Flanagan, Katrien van Bocxlaer, Evangelia-Theophano Piperaki, Vanessa Yardley, Simon L Croft, John Tyson, Sam P Whitehouse, Jonathan O’Halloran, Sanjeev Krishna, Henry M Staines

Supplemental file 1 for: An efficient and novel technology for the extraction of parasite genomic DNA from whole blood or culture

Supplementary Figure 1: Plasmodium falciparumDNA from spiked whole blood determined by PfBetatubulin PCR. A and B. low volume eluate template, 1 μl C and D. high volume eluate template, 10 μl. Two extractions run per parasitaemia condition. M: 100bp marker, NTC: No template control. Percentage denotes the parasitaemia post spiking.

Supplementary Figure 2: Plasmodium falciparumDNA from spiked whole blood determined by PfBetatubulin PCR. A and B. low volume eluate template, 1 μl C and D. high volume eluate template, 10 μl. Two extractions run per parasitaemia condition. M: 100bp marker, NTC: No template control. Percentage denotes the parasitaemia post spiking.

Funding

We gratefully acknowledge support for this work from the European Community’s Seventh Framework Programme (FP7/2007-2013), NANOMAL under grant agreement N° 304948 to SK, HMS, SW and JOH and the MRC Confidence in Concept, award number MC_PC_14111 (2014 – 2015), to SLC, HMS and SK. HMS is supported by the Wellcome Trust Institutional Strategic Support Fund (204809/Z/16/Z) awarded to St. George’s University of London. The funders had no role in the design of the study, data collection, analysis or preparation of the manuscript. MF, JT, SPW and JO’H work for QuantuMDx, the company that developed DNA-XT. SK is a paid advisor and chairs the infectious diseases advisory board for QuantuMDx. SK and HMS are both shareholders in QuantuMDx. SK and HMS are in receipt of funds from QuantuMDx to develop diagnostic technologies and assays (that have supported DJC and CMM). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

History

Usage metrics

    BioTechniques

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC